ESTRO 2022 - Abstract Book

S1599

Abstract book

ESTRO 2022

patients had a CTV_HR dose >90Gy. 88.1% of patients had a Bladder D2cc <90Gy. 90% of patients had a Rectum D2cc <75Gy. All patients met the planning limit for the sigmoid. TRAK decreased with new brachytherapy system. Conclusion This demonstrates that evidence based IGABT planning aims can be delivered using the two major brachytherapy commercial systems. Applicator choice makes a difference to the treatment plan quality parameters. References: 1. Pötter R, Tanderup K, Kirisits C etal. The EMBRACE II Study: The Outcome and Prospect of Two Decades of Evolution within the GEC-ESTRO GYN Working Group and the EMBRACE Studies. Clinical and Translational Radiation Oncology 2018;9:48–60. 2. Tanderup, K, Nesvacil N, Kirchheiner K etal. Evidence-Based Dose Planning Aims and Dose Prescription in Image-Guided Brachytherapy Combined With Radiochemotherapy in Locally Advanced Cervical Cancer. Seminars in Radiation Oncology 2020;30 (4):311–27. P. Vicente Ruiz 1 , B. Vazquez Barreiro 1 , L. Rodriguez Ruiz 1 , J.L. Guinot Rodriguez 1 , M. Tortajada Azcutia 1 , M.A. Santos Olias 1 , V. Gonzalez Perez 2 , A. de la Rosa de los Rios 1 , L. Arribas Alpuente 1 1 Fundación Instituto Valenciano de Oncología, Radiation Oncology, Valencia, Spain; 2 Fundación Instituto Valenciano de Oncología, Radiophysics, Valencia, Spain Purpose or Objective Brachytherapy (BT) is mainstay in the standard of care for patients receiving primary curative-intent for locally advanced cervical cancer because it is the best technique to deliver significantly higher doses to the target while minimizing dose to the normal tissues. Interstitial BT allows for better dosimetry and higher doses. We analyze Progression-free survival (PFS) in terms of local, regional (defined as pelvic relapse) and distant relapse rate, time to local progression, overall survival (OS) and toxicity. Materials and Methods We retrospectively evaluated patients with locally advanced cancer stage IB-IVB (FIGO Staging System 2018) of the cervix who completed treatment with EBRT to a total dose of 50 Gy (encompassing primary tumor and regional pelvic lymphatic nodes) with concurrent cisplatin-based chemotherapy and Ir-192 endocavitary and interstitial BT. It was guided by computed tomography or magnetic resonance image. Dose is prescribed to the HR-CTV (including cervix and parametrial involvement). We recorded total dose to the isodose D90 of the HR-CTV, maximum dose to 2 cc bladder, rectum and sigma (DV2cc, DR2cc and DS2cc). Toxicity was reported according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.0. PO-1793 Clinical outcomes after interstitial HDR brachytherapy for locally advanced cervical cancer

Results We recruited 35 women with primary squamous cell carcinoma (n=30), adenocarcinoma (n=4), and neuroendocrine (n=1) carcinoma of the cervix who have been treated between 2015 and 2020. The median age at diagnosis was 49 years (25-71 years). Eight (22.8%) patients underwent paraaortical lymphadenectomy and 12 (34.3%) patients received EBRT to paraaortics. Twenty-one (60%) patients had concomitant boost to affected lymph nodes. Total mean dose of both EBRT and BT was EQD2 86.3 ± 2.3 Gy, completed in an average of time of 59 days. After a median follow-up of 34.5 months (6-74 months), 28 women are alive and 23 remain disease-free. The OS was 84.9% at 24 months, and 80.2% at 36 months. Only 4 women presented local relapse and it occurred before 15 months. Eleven patients (31.43%) had extrapelvic metastases in bone (n=2), lung (n=2), liver (n=1), CNS (n=2), and distant lymph nodes (n=8). The maximum EQD2 to the 2 cc of bladder, rectum, and sigma was 75.4 ± 6.6 Gy, 66.1 ± 7.4 Gy, 65 ± 12.6 Gy respectively (mean ± standard deviation). No grade ≥ 3 urinary, gynecological or rectal toxicities have been observed to date. Three patients presented grade 2 rectovaginal fistula and one patient presented grade 1 proctitis. Every registered death (n=7) was due to disease progression.